Senescent Cells: A Therapeutic Target in Cardiovascular Diseases
Senescent cell accumulation has been observed in age-associated diseases including cardiovascular diseases. Senescent cells lack proliferative capacity and secrete senescence-associated secretory phenotype (SASP) factors that may cause or worsen many cardiovascular diseases. Therapies targeting sene...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/12/9/1296 |
| _version_ | 1797602840897650688 |
|---|---|
| author | Masayoshi Suda Karl H. Paul Tohru Minamino Jordan D. Miller Amir Lerman Georgina M. Ellison-Hughes Tamar Tchkonia James L. Kirkland |
| author_facet | Masayoshi Suda Karl H. Paul Tohru Minamino Jordan D. Miller Amir Lerman Georgina M. Ellison-Hughes Tamar Tchkonia James L. Kirkland |
| author_sort | Masayoshi Suda |
| collection | DOAJ |
| description | Senescent cell accumulation has been observed in age-associated diseases including cardiovascular diseases. Senescent cells lack proliferative capacity and secrete senescence-associated secretory phenotype (SASP) factors that may cause or worsen many cardiovascular diseases. Therapies targeting senescent cells, especially senolytic drugs that selectively induce senescent cell removal, have been shown to delay, prevent, alleviate, or treat multiple age-associated diseases in preclinical models. Some senolytic clinical trials have already been completed or are underway for a number of diseases and geriatric syndromes. Understanding how cellular senescence affects the various cell types in the cardiovascular system, such as endothelial cells, vascular smooth muscle cells, fibroblasts, immune cells, progenitor cells, and cardiomyocytes, is important to facilitate translation of senotherapeutics into clinical interventions. This review highlights: (1) the characteristics of senescent cells and their involvement in cardiovascular diseases, focusing on the aforementioned cardiovascular cell types, (2) evidence about senolytic drugs and other senotherapeutics, and (3) the future path and clinical potential of senotherapeutics for cardiovascular diseases. |
| first_indexed | 2024-03-11T04:22:13Z |
| format | Article |
| id | doaj.art-60205bf4c27a4be98e6b5b48c2e00034 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-11T04:22:13Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-60205bf4c27a4be98e6b5b48c2e000342023-11-17T22:43:59ZengMDPI AGCells2073-44092023-05-01129129610.3390/cells12091296Senescent Cells: A Therapeutic Target in Cardiovascular DiseasesMasayoshi Suda0Karl H. Paul1Tohru Minamino2Jordan D. Miller3Amir Lerman4Georgina M. Ellison-Hughes5Tamar Tchkonia6James L. Kirkland7Department of Physiology and Biomedical Engineering, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USADepartment of Physiology and Biomedical Engineering, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USADepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 3-1-3 Hongo, Bunkyo-ku, Tokyo 113-8421, JapanDivision of Cardiovascular Surgery, Mayo Clinic College of Medicine, 200 First St., S.W., Rochester, MN 55905, USADepartment of Cardiovascular Medicine, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USACentre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences & Medicine, Guy’s Campus, King’s College London, London SE1 1UL, UKDepartment of Physiology and Biomedical Engineering, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USADepartment of Physiology and Biomedical Engineering, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USASenescent cell accumulation has been observed in age-associated diseases including cardiovascular diseases. Senescent cells lack proliferative capacity and secrete senescence-associated secretory phenotype (SASP) factors that may cause or worsen many cardiovascular diseases. Therapies targeting senescent cells, especially senolytic drugs that selectively induce senescent cell removal, have been shown to delay, prevent, alleviate, or treat multiple age-associated diseases in preclinical models. Some senolytic clinical trials have already been completed or are underway for a number of diseases and geriatric syndromes. Understanding how cellular senescence affects the various cell types in the cardiovascular system, such as endothelial cells, vascular smooth muscle cells, fibroblasts, immune cells, progenitor cells, and cardiomyocytes, is important to facilitate translation of senotherapeutics into clinical interventions. This review highlights: (1) the characteristics of senescent cells and their involvement in cardiovascular diseases, focusing on the aforementioned cardiovascular cell types, (2) evidence about senolytic drugs and other senotherapeutics, and (3) the future path and clinical potential of senotherapeutics for cardiovascular diseases.https://www.mdpi.com/2073-4409/12/9/1296cellular senescencesenolyticsSASPatherosclerosiscardiovascular diseases |
| spellingShingle | Masayoshi Suda Karl H. Paul Tohru Minamino Jordan D. Miller Amir Lerman Georgina M. Ellison-Hughes Tamar Tchkonia James L. Kirkland Senescent Cells: A Therapeutic Target in Cardiovascular Diseases Cells cellular senescence senolytics SASP atherosclerosis cardiovascular diseases |
| title | Senescent Cells: A Therapeutic Target in Cardiovascular Diseases |
| title_full | Senescent Cells: A Therapeutic Target in Cardiovascular Diseases |
| title_fullStr | Senescent Cells: A Therapeutic Target in Cardiovascular Diseases |
| title_full_unstemmed | Senescent Cells: A Therapeutic Target in Cardiovascular Diseases |
| title_short | Senescent Cells: A Therapeutic Target in Cardiovascular Diseases |
| title_sort | senescent cells a therapeutic target in cardiovascular diseases |
| topic | cellular senescence senolytics SASP atherosclerosis cardiovascular diseases |
| url | https://www.mdpi.com/2073-4409/12/9/1296 |
| work_keys_str_mv | AT masayoshisuda senescentcellsatherapeutictargetincardiovasculardiseases AT karlhpaul senescentcellsatherapeutictargetincardiovasculardiseases AT tohruminamino senescentcellsatherapeutictargetincardiovasculardiseases AT jordandmiller senescentcellsatherapeutictargetincardiovasculardiseases AT amirlerman senescentcellsatherapeutictargetincardiovasculardiseases AT georginamellisonhughes senescentcellsatherapeutictargetincardiovasculardiseases AT tamartchkonia senescentcellsatherapeutictargetincardiovasculardiseases AT jameslkirkland senescentcellsatherapeutictargetincardiovasculardiseases |